Protease Inhibitors : Candidate Drugs to Inhibit Severe Acute Respiratory Syndrome Coronavirus 2 Replication
The number of patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has rapidly increased, although the WHO declared a pandemic. However, drugs that function against SARS-CoV-2 have not been established. SARS-CoV-2 has been suggested to bind angiotensin-converting enzyme 2, the receptor of the SARS coronavirus. SARS coronavirus and coronavirus 229E, the cause of the common cold, replicate through cell-surface and endosomal pathways using a protease, the type II transmembrane protease. To examine the effects of protease inhibitors on the replication of coronavirus 229E, we pretreated primary cultures of human nasal epithelial (HNE) cells with camostat or nafamostat, each of which has been used for the treatment of pancreatitis and/or disseminated intravascular coagulation. HNE cells were then infected with coronavirus 229E, and viral titers in the airway surface liquid of the cells were examined. Pretreatment with camostat (0.1-10 μg/mL) or nafamostat (0.01-1 μg/mL) reduced the titers of coronavirus 229E. Furthermore, a significant amount of type II transmembrane protease protein was detected in the airway surface liquid of HNE cells. Additionally, interferons have been reported to have antiviral effects against SARS coronavirus. The additive effects of interferons on the inhibitory effects of other candidate drugs to treat SARS-CoV-2 infection, such as lopinavir, ritonavir and favipiravir, have also been studied. These findings suggest that protease inhibitors of this type may inhibit coronavirus 229E replication in human airway epithelial cells at clinical concentrations. Protease inhibitors, interferons or the combination of these drugs may become candidate drugs to inhibit the replication of SARS-CoV-2.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:251 |
|---|---|
| Enthalten in: |
The Tohoku journal of experimental medicine - 251(2020), 1 vom: 31. Mai, Seite 27-30 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Yamaya, Mutsuo [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 29.05.2020 Date Revised 04.12.2021 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1620/tjem.251.27 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM310309913 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM310309913 | ||
| 003 | DE-627 | ||
| 005 | 20231225135823.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1620/tjem.251.27 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1034.xml |
| 035 | |a (DE-627)NLM310309913 | ||
| 035 | |a (NLM)32448818 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Yamaya, Mutsuo |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Protease Inhibitors |b Candidate Drugs to Inhibit Severe Acute Respiratory Syndrome Coronavirus 2 Replication |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 29.05.2020 | ||
| 500 | |a Date Revised 04.12.2021 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a The number of patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has rapidly increased, although the WHO declared a pandemic. However, drugs that function against SARS-CoV-2 have not been established. SARS-CoV-2 has been suggested to bind angiotensin-converting enzyme 2, the receptor of the SARS coronavirus. SARS coronavirus and coronavirus 229E, the cause of the common cold, replicate through cell-surface and endosomal pathways using a protease, the type II transmembrane protease. To examine the effects of protease inhibitors on the replication of coronavirus 229E, we pretreated primary cultures of human nasal epithelial (HNE) cells with camostat or nafamostat, each of which has been used for the treatment of pancreatitis and/or disseminated intravascular coagulation. HNE cells were then infected with coronavirus 229E, and viral titers in the airway surface liquid of the cells were examined. Pretreatment with camostat (0.1-10 μg/mL) or nafamostat (0.01-1 μg/mL) reduced the titers of coronavirus 229E. Furthermore, a significant amount of type II transmembrane protease protein was detected in the airway surface liquid of HNE cells. Additionally, interferons have been reported to have antiviral effects against SARS coronavirus. The additive effects of interferons on the inhibitory effects of other candidate drugs to treat SARS-CoV-2 infection, such as lopinavir, ritonavir and favipiravir, have also been studied. These findings suggest that protease inhibitors of this type may inhibit coronavirus 229E replication in human airway epithelial cells at clinical concentrations. Protease inhibitors, interferons or the combination of these drugs may become candidate drugs to inhibit the replication of SARS-CoV-2 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a camostat | |
| 650 | 4 | |a coronavirus 229E | |
| 650 | 4 | |a nafamostat | |
| 650 | 4 | |a type II transmembrane protease | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 650 | 7 | |a Benzamidines |2 NLM | |
| 650 | 7 | |a Culture Media, Conditioned |2 NLM | |
| 650 | 7 | |a Esters |2 NLM | |
| 650 | 7 | |a Guanidines |2 NLM | |
| 650 | 7 | |a Protease Inhibitors |2 NLM | |
| 650 | 7 | |a Spike Glycoprotein, Coronavirus |2 NLM | |
| 650 | 7 | |a spike protein, SARS-CoV-2 |2 NLM | |
| 650 | 7 | |a camostat |2 NLM | |
| 650 | 7 | |a 0FD207WKDU |2 NLM | |
| 650 | 7 | |a Gabexate |2 NLM | |
| 650 | 7 | |a 4V7M9137X9 |2 NLM | |
| 650 | 7 | |a Serine Endopeptidases |2 NLM | |
| 650 | 7 | |a EC 3.4.21.- |2 NLM | |
| 650 | 7 | |a TMPRSS2 protein, human |2 NLM | |
| 650 | 7 | |a EC 3.4.21.- |2 NLM | |
| 650 | 7 | |a nafamostat |2 NLM | |
| 650 | 7 | |a Y25LQ0H97D |2 NLM | |
| 700 | 1 | |a Nishimura, Hidekazu |e verfasserin |4 aut | |
| 700 | 1 | |a Deng, Xue |e verfasserin |4 aut | |
| 700 | 1 | |a Kikuchi, Akiko |e verfasserin |4 aut | |
| 700 | 1 | |a Nagatomi, Ryoichi |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Tohoku journal of experimental medicine |d 1950 |g 251(2020), 1 vom: 31. Mai, Seite 27-30 |w (DE-627)NLM000023612 |x 1349-3329 |7 nnns |
| 773 | 1 | 8 | |g volume:251 |g year:2020 |g number:1 |g day:31 |g month:05 |g pages:27-30 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1620/tjem.251.27 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 251 |j 2020 |e 1 |b 31 |c 05 |h 27-30 | ||